Full Press Release Details
CONDENSED CONSOLIDATED INTERIM FINANCIAL
(Expressed in United States dollars)
FOR THE THREE MONTHS ENDED DECEMBER 31, 2017
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF
(Expressed in United States dollars)
| December 31, 2017 | September 30, 2017 | |||||||
| ASSETS | ||||||||
| Current | ||||||||
| Cash | $ | 1,867,823 | $ | 3,957,185 | ||||
| Receivables | 23,769 | 29,475 | ||||||
| Prepaids (Note 4) | 793,489 | 1,072,103 | ||||||
| 2,685,081 | 5,058,763 | |||||||
| Equipment (Note 5) | 94,485 | 99,882 | ||||||
| Intangible assets (Note 6) | 232,751 | 237,326 | ||||||
| Deferred financing costs (Note 9) | 420,917 | 211,073 | ||||||
| Total assets | $ | 3,433,234 | $ | 5,607,044 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY) | ||||||||
| Current | ||||||||
| Accounts payable and accrued liabilities | $ | 1,501,037 | $ | 1,641,103 | ||||
| Current portion of long-term debt (Note 7) | 2,718,117 | 2,026,588 | ||||||
| Income tax payable | 109,521 | 109,521 | ||||||
| 4,328,675 | 3,777,212 | |||||||
| Long-term debt (Note 7) | 5,339,762 | 5,933,092 | ||||||
| Derivative liabilities (Note 8) | 82,180 | 170,743 | ||||||
| Total liabilities | 9,750,617 | 9,881,047 | ||||||
| Shareholders' equity (deficiency) | ||||||||
| Share capital (Note 9) | 25,980,117 | 25,980,117 | ||||||
| Reserves (Note 10) | 4,650,393 | 4,562,005 | ||||||
| Accumulated other comprehensive loss | (2,076,479 | ) | (2,076,479 | ) | ||||
| Deficit | (34,871,414 | ) | (32,739,646 | ) | ||||
| (6,317,383 | ) | (4,274,003 | ) | |||||
| Total liabilities and shareholders' equity (deficiency) | $ | 3,433,234 | $ | 5,607,044 |
Nature and continuance of operations (Note
Commitments (Note 17)
Subsequent events (Note 19)
| On behalf of the Board on February 13, 2018 | |||
| "David R. Parkinson" | Director | "Franklin Berger" | Director |
The accompanying notes are an integral part
of these condensed consolidated interim financial statements.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF
LOSS AND COMPREHENSIVE LOSS
(Expressed in United States dollars)
FOR THE THREE MONTHS ENDED DECEMBER 31
| 2017 | 2016 | |||||||
| OPERATING EXPENSES | ||||||||
| Research and development, net of recoveries (Note 18) | $ | 969,597 | $ | (908,493 | ) | |||
| Financing costs | 244,810 | 93,090 | ||||||
| General and administration, net of recoveries (Note 18) | 958,375 | 1,369,819 | ||||||
| Total operating expenses | (2,172,782 | ) | (554,416 | ) | ||||
| Foreign exchange | (5,722 | ) | 6,406 | |||||
| Gain on derivative liability (Note 8) | 88,563 | 1,994,375 | ||||||
| Net income (loss) for the period before taxes | (2,089,941 | ) | 1,446,365 | |||||
| Income tax recovery (expense) | (41,827 | ) | 18,097 | |||||
| Net income (loss) and comprehensive income (loss) for the period | $ | (2,131,768 | ) | $ | 1,464,462 | |||
| Basic and diluted earnings (loss) per common share | ||||||||
| Earnings (loss) per share - basic (Note 11) | $ | (0.07 | ) | $ | 0.05 | |||
| Earnings (loss) per share - diluted (Note 11) | $ | (0.07 | ) | $ | 0.05 | |||
| Weighted average number of common shares outstanding - basic | 29,101,889 | 29,096,889 | ||||||
| Weighted average number of common shares outstanding - diluted | 29,101,889 | 31,852,690 |
The accompanying notes are an integral part
of these condensed consolidated interim financial statements.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF
(Expressed in United States dollars)
FOR THE THREE MONTHS ENDED DECEMBER 31
| 2017 | 2016 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Income (loss) for the period | $ | (2,131,768 | ) | $ | 1,464,462 | |||
| Items not affecting cash: | ||||||||
| Amortization | 9,972 | 11,536 | ||||||
| Gain on derivative liability | (88,563 | ) | (1,994,375 | ) | ||||
| Finance expense | 244,810 | 93,090 | ||||||
| Product development and relocation grant | - | (3,992,799 | ) | |||||
| Unrealized foreign exchange | (18,114 | ) | (587,292 | ) | ||||
| Share-based payments (Note 10) | 88,388 | 333,428 | ||||||
| Changes in non-cash working capital items: | ||||||||
| Receivables | 5,967 | (8,624 | ) | |||||
| Prepaid expenses | 278,614 | 286,147 | ||||||
| Accounts payable and accrued liabilities4 | (332,030 | ) | (2,158,988 | ) | ||||
| Net cash used in operating activities | (1,942,724 | ) | (6,553,415 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds on loan advance | - | 8,000,000 | ||||||
| Financing costs | - | (156,895 | ) | |||||
| Interest paid | (146,611 | ) | (13,000 | ) | ||||
| Net cash provided by (used in) financing activities | (146,611 | ) | 7,830,105 | |||||
| Effect of foreign exchange on cash | (27 | ) | 596,968 | |||||
| Change in cash for the period | (2,089,362 | ) | 1,873,658 | |||||
| Cash, beginning of period | 3,957,185 | 8,985,095 | ||||||
| Cash, end of period | $ | 1,867,823 | $ | 10,858,753 |
Supplemental Cash Flow Information (Note
The accompanying notes are an integral part
of these condensed consolidated interim financial statements.
CONDENSED CONSOLIDATED INTERIM STATEMENT OF
CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)
(Expressed in United States dollars)
| Reserves | ||||||||||||||||||||||||||||
| Number of shares | Share capital | Share-based payments | Warrants | Cumulative translation adjustment | Deficit | Total | ||||||||||||||||||||||
| Balance, September 30, 2016 | 29,096,889 | $ | 25,974,742 | $ | 3,496,221 | $ | 309,293 | $ | (2,076,479 | ) | $ | (28,240,634 | ) | $ | (536,857 | ) | ||||||||||||
| Share-based payments | - | - | 333,428 | - | - | - | 333,428 | |||||||||||||||||||||
| Income (loss) for the period | - | - | - | - | - | 1,464,462 | 1,464,462 | |||||||||||||||||||||
| Balance, December 31, 2016 | 29,096,889 | $ | 25,974,742 | $ | 3,829,649 | $ | 309,293 | $ | (2,076,479 | ) | $ | (26,776,172 | ) | $ | 1,261,033 | |||||||||||||
| Options exercised | 5,000 | 5,375 | (2,436 | ) | - | - | - | 2,939 | ||||||||||||||||||||
| Share-based payments | - | - | 425,499 | - | - | - | 425,499 | |||||||||||||||||||||
| Loss for the period | - | - | - | - | - | (5,963,474 | ) | (5,963,474 | ) | |||||||||||||||||||
| Balance, September 30, 2017 | 29,101,889 | $ | 25,980,117 | $ | 4,252,712 | $ | 309,293 | $ | (2,076,479 | ) | $ | (32,739,646 | ) | $ | (4,274,003 | ) | ||||||||||||
| Share-based payments | - | - | 88,388 | - | - | - | 88,388 | |||||||||||||||||||||
| Loss for the period | - | - | - | - | - | (2,131,768 | ) | (2,131,768 | ) | |||||||||||||||||||
| Balance, December 31, 2017 | 29,101,889 | $ | 25,980,117 | $ | 4,341,100 | $ | 309,293 | $ | (2,076,479 | ) | $ | (34,871,414 | ) | $ | (6,317,383 | ) |
The accompanying notes are an integral part
of these condensed consolidated interim financial statements.
NOTES TO THE CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS
(Expressed in United States dollars)
FOR THE THREE MONTHS ENDED DECEMBER 31, 2017
AND CONTINUANCE OF OPERATIONS
Nature of Operations
ESSA Pharma Inc. (the "Company")
was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company's head office address
is Suite 720 - 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26th Floor
at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the NASDAQ Capital Market ("NASDAQ")
under the symbol "EPIX", and on the Toronto Venture Exchange ("TSX-V") under the symbol "EPI".
The Company is focused on the development
of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the "NTD
Technology") which were the joint property of the British Columbia Cancer Agency and the University of British Columbia.
As at December 31, 2017, no products are in commercial production or use. From November 2015 until September 2017, the Company's
primary activity was the Phase I clinical development of clinical candidate EPI-506. On September 11, 2017, the Company announced
its decision to discontinue further clinical development of EPI-506 and to implement a corporate restructuring plan to focus research
and development resources on its next-generation compounds. The restructuring included a decrease in headcount and reduction of
operational expenditures related to the clinical program.
These financial statements have been
prepared in accordance with International Financial Reporting Standards ("IFRS") assuming the Company will continue
on a going-concern basis. The Company has incurred losses and negative operating cash flows since inception. The Company incurred
a net loss of $2,131,768 during the three months ended December 31, 2017 and has an accumulated deficit of $34,871,414. The ability
of the Company to continue as a going concern in the long-term depends upon its ability to develop profitable operations and to
continue to raise adequate financing. As at December 31, 2017, the Company has not advanced its research into a commercially
viable product. The Company's continuation as a going concern is dependent upon the successful development of its NTD Technology
to a commercial standard.
Subsequent to December 31, 2017,
the Company completed a financing of $26,000,000 in gross proceeds (Note 19). Management continues to seek sources of additional
financing which would assure continuation of the Company's operations and research programs. However, there is no certainty
that such financing will be provided or provided on favorable terms. Management believes that it will complete a financing in sufficient
time to continue to execute its planned expenditures without interruption.
Statement of Compliance
These condensed consolidated interim
financial statements, including comparatives, have been prepared in accordance with International Accounting Standards ("IAS")
34 Interim Financial Reporting' ("IAS 34") using accounting policies consistent with International Financial
Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations
of the International Financial Reporting Interpretations Committee ("IFRIC").
The condensed consolidated interim
financial statements do not include all the information and disclosures required in the annual consolidated financial statements
and should be read in conjunction with the Company's annual consolidated financial statements for the year ended September
NOTES TO THE CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS
(Expressed in United States dollars)
FOR THE THREE MONTHS ENDED DECEMBER 31, 2017
OF PRESENTATION (cont'd...)
Basis of Presentation
The condensed consolidated interim
financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value.
In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting,
except for cash flow information.
All amounts expressed in these condensed
consolidated interim financial statements and the accompanying notes are expressed in United States dollars, except per share data
and where otherwise indicated. References to "$" are to United States dollars and references to "C$" are
to Canadian dollars.
Basis of Consolidation
The condensed consolidated interim
financial statements comprise the accounts of ESSA Pharma Inc., the parent company, and its wholly-owned subsidiary, ESSA Pharmaceuticals
Corp., after the elimination of all material intercompany balances and transactions.
Subsidiaries are all entities over
which the Company has exposure to variable returns from its involvement and has the ability to use power over the investee to affect
its returns. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when
assessing whether the Company controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred
to the Company until the date on which control ceases.
The accounts of subsidiaries are
prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions,
balances and unrealized gains or losses on transactions are eliminated upon consolidation.
Functional and Presentation Currency